Abstract
"Teva has a robust corporate strategy that should serve it well for years to
come, driving strong growth and further innovation. Teva is therefore one of
the most exciting and dynamic companies in the global pharmaceutical
industry," finds visiongain report
Just some of the recent headlines surrounding Teva:
- Court rules against Teva in patent dispute - May 11th
- Teva gets tentative ok for generic of Eli Lilly' s Gemzar - May 8th
- Teva Announces Approval and Shipment of Generic Omnicef - May 14th
- Teva loses Merck generics race to U.S. rival Mylan - May 14th
In 2006, Teva Pharmaceutical Industries generated $8408m in net sales
worldwide from both innovative branded and generic drugs, firmly establishing
itself as a Top-20 international pharmaceutical company and leader in
generics. That performance reflects rapid growth in recent years, as
represented by a tripling in sales from $2519m in 2002. By 2010, total sales
for Teva should reach $13.3bn. These are some of the findings from the "Teva
Pharmaceutical Industries Market Forecasts 2007-2012" report, published by the
business information company visiongain.
Report author Dr Gordon Low said: "With spectacular sales growth in recent
quarters, Teva will raise its profile even higher in the global pharmaceutical
sector. Growth will be particularly evident in branded generics and innovative
products. In particular, there will be significant developments in NCE
development and international business, including further launches of
innovative therapeutic molecules later this decade and early in the next."
Stakeholders in the industry therefore cannot afford to ignore developments in
Teva.
The purpose of this visiongain report is to examine the commercial prospects
for Teva Pharmaceutical Industries in the global healthcare market. Teva is
already competing well there, especially in key market segments and developing
geographical markets. Its profile as a leading generics and innovation-driven
pharmaceutical company will continue to rise. Teva Pharmaceutical Industries
2007-2012, critically examines that company through comprehensive research,
market forecasting and qualitative analyses.
Teva' s leading product is Copaxone, for multiple sclerosis, which generated
$1414m during 2006. Other revenues are generated from a wide portfolio of
generic pharmaceutical products and another innovative drug, Azilect, a
treatment for Parkinson' s disease. Teva also produces and markets active
pharmaceutical ingredients (APIs) for the industry worldwide.
After its acquisition of generics rival -Ivax Corporation - in a deal
finalised in early 2006, Teva achieved overall leadership of the global
generics market. Teva clearly has a robust corporate strategy that should
serve it well for years to come, driving strong growth and further innovation.
Teva is therefore one of the most exciting and dynamic companies in the global
pharmaceutical industry, visiongain believes. Consequently, participants in
the global market should pay close attention to developments in Teva.
Teva Pharmaceutical Industries 2007-2012 examines that company critically,
through comprehensive research and analysis. Importantly, visiongain discusses
Teva in the context of the wider pharmaceutical market. This market-based
research involved a detailed study of commercial documents, databases, company
reports and relevant news. Importantly, visiongain applied techniques such as
financial forecasting, SWOT analysis and qualitative projections.
In particular, Teva Pharmaceutical Industries 2007-2012 concentrates on the
following essential aspects of that company:
- Detailed analysis of Teva' s divisions and the performance of its products
- Sales forecasts for all Teva' s divisions and the overall group
- Sales forecasts for Teva' s innovative drugs - Copaxone and Azilect
- Discussions of issues affecting the relevant market segments
- Competitor analysis
- Drivers and opportunities for Teva
- Restraints and threats facing the company
- Discussions of corporate strategy in the context of the market
- Strategic alliances and licensing
- International operations
- Pipeline developments and their implications for the future
Leading generics companies such as Teva have established a new paradigm in the
generics sector: that of developing innovative drugs. Other international
generics companies are in a race to catch up with Teva, the world' s leader in
generics and a Top-20 pharmaceutical company in its own right. Teva has
already achieved success with its leading innovative product Copaxone.
Visiongain predicts that Teva' s sales revenues will continue to rise strongly,
as it harnesses opportunities in the expanding generics market and makes
further progress as a global discovery-led company.
Unique benefits to you when you order this report
- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using
harddrive space
- Primary research throughout. You will not find this information anywhere
else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
View Cart
